Patents by Inventor Guru Reddy

Guru Reddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110311481
    Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).
    Type: Application
    Filed: August 29, 2011
    Publication date: December 22, 2011
    Applicants: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, SPECTRUM PHARMACEUTICALS, INC.
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Publication number: 20110288143
    Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.
    Type: Application
    Filed: April 8, 2011
    Publication date: November 24, 2011
    Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
  • Publication number: 20110275696
    Abstract: The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy.
    Type: Application
    Filed: March 8, 2011
    Publication date: November 10, 2011
    Inventors: Steffan Nawrocki, Jennifer Carew, Guru Reddy
  • Patent number: 8030278
    Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: October 4, 2011
    Assignees: Spectrum Pharmaceuticals, Inc., Board of Trustees University of Illinois
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Patent number: 8026216
    Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: September 27, 2011
    Assignees: Spectrum Pharmaceuticals, Inc., Board of Trustees University of Illinois
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Publication number: 20090221615
    Abstract: The present disclosure relates to methods of treating cancer in mammals by administration of Lucanthone and at least one anti-metabolite. Pharmaceutical compositions and kits comprising Lucanthone and at least one anti-metabolite also are disclosed.
    Type: Application
    Filed: February 19, 2009
    Publication date: September 3, 2009
    Inventors: Guru Reddy, Luigi Lenaz
  • Publication number: 20090163570
    Abstract: Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments.
    Type: Application
    Filed: March 2, 2009
    Publication date: June 25, 2009
    Inventors: Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
  • Publication number: 20090155206
    Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
    Type: Application
    Filed: February 20, 2009
    Publication date: June 18, 2009
    Applicants: Spectrum Pharmaceuticals, Inc., The Board of Trustees of the University of Illinois
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Publication number: 20080318846
    Abstract: Methods to sensitize tumor cells to radiation therapy through the administration of an endothelin agonist such as the ETB agonist IRL1620.
    Type: Application
    Filed: August 27, 2007
    Publication date: December 25, 2008
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Publication number: 20080253994
    Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).
    Type: Application
    Filed: April 10, 2008
    Publication date: October 16, 2008
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Publication number: 20080181971
    Abstract: Disclosed herein are methods relating to combination cancer treatments that include elsamitrucin and other agents.
    Type: Application
    Filed: January 25, 2008
    Publication date: July 31, 2008
    Inventors: Guru Reddy, Luigi Lenaz
  • Publication number: 20070293445
    Abstract: Stable solid, crystalline forms of elsamitrucin salts are provided that are useful in preparing anti-neoplastic parenteral formulations. Also provided are methods for treating neoplastic diseases in humans using parenteral formulations that include at least one stable elsamitrucin salt.
    Type: Application
    Filed: June 15, 2006
    Publication date: December 20, 2007
    Applicant: SPECTRUM PHARMACEUTICALS, INC.
    Inventors: Ashok Gore, Fred Defesche, Hemant Joshi, Guru Reddy, Luigi Lenaz, Paul K. Isbester, Olga V. Lapina, Grant J. Palmer, Jonathon S. Salsbury
  • Publication number: 20070185188
    Abstract: Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments.
    Type: Application
    Filed: February 9, 2007
    Publication date: August 9, 2007
    Inventors: Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
  • Publication number: 20070032422
    Abstract: Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of a chemotherapeutic agent.
    Type: Application
    Filed: August 2, 2006
    Publication date: February 8, 2007
    Applicants: SPECTRUM PHARMACEUTICALS, INC., The Board of Trustees of the University of Illinois
    Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
  • Publication number: 20060223876
    Abstract: This invention generally relates to Indoloquinone caused tumor radiation therapy sensitization. More specifically, this invention relates to the discovery of indoloquinones as a radiation sensitizer (radiation therapy adjuvant) due to its ability to selectively target hypoxic cells and to damage the DNA of these hypoxic cells. Indoloquinones do so with minimal normal cell and tissue toxicity.
    Type: Application
    Filed: March 31, 2006
    Publication date: October 5, 2006
    Inventors: Randy Burd, Luigi Lenaz, Shanta Chawla, Guru Reddy, Adam Dicker